Covestor’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Sell
63
-42
-40% – ﹤0.01% 2730
2026
Q2
$0 Buy
105
+74
+239% – ﹤0.01% 2769
2026
Q1
$0 Hold
31
– – ﹤0.01% 2671
2025
Q4
$0 Hold
31
– – ﹤0.01% 2642
2025
Q3
$0 Hold
31
– – ﹤0.01% 2660
2025
Q2
$0 Sell
31
-2
-6% – ﹤0.01% 2638
2025
Q1
$0 Buy
33
+19
+136% – ﹤0.01% 2618
2024
Q4
$0 Buy
14
+1
+8% – ﹤0.01% 2626
2024
Q3
$0 Sell
13
-1
-7% – ﹤0.01% 2635
2024
Q2
$0 Hold
14
– – ﹤0.01% 2638
2024
Q1
$0 Sell
14
-1
-7% – ﹤0.01% 2625
2023
Q4
$0 Buy
15
+7
+88% – ﹤0.01% 2583
2023
Q3
$0 Sell
8
-1
-11% – ﹤0.01% 2576
2023
Q2
$0 Hold
9
– – ﹤0.01% 2527
2023
Q1
$0 Buy
+9
New – ﹤0.01% 2453

Other funds holding PRME

Covestor's PRME Position: Q3 2026 in Review

Covestor reduced its Prime Medicine (PRME) stake by 40% in Q3 2026, cutting 42 shares and leaving 63 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

Covestor first reported a position in PRME in Q1 2023 and has held it in 15 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Covestor held 63 shares of Prime Medicine worth $0 as of Q3 2026.
  • Covestor sold 42 Prime Medicine shares in Q3 2026.
  • Prime Medicine made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2730 holding.
  • Covestor first reported a position in Prime Medicine in Q1 2023 and has held it in 15 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.